Worthy, the signature demonstrated to predict poor outcomes in breast cancer patients exhibiting high transcriptional levels of ITGA11, THBS1, FN1, EMP1, ITGA2, FYN, SPP1, and EMP2. Here, EMP1 is linked to breast carcinoma.